ADVM · As filed with the SEC
Adverum Biotechnologies income statement, by fiscal year
The statement as Adverum Biotechnologies presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS · USD thousands, except per-share amounts; shares in thousands
| USD thousands, except per-share amounts; shares in thousands | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 | FY2018 Year ended Dec 31, 2018 | FY2017 Year ended Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|
| License revenue | 1,000 | 3,600 | 0 | 7,500 | 0 | 250 | 1,612 | — |
| Operating expenses: | ||||||||
| Research and development | 77,041 | 77,676 | 99,277 | 89,181 | 73,309 | 40,419 | 50,133 | 39,839 |
| General and administrative | 63,118 | 49,915 | 57,858 | 64,441 | 44,641 | 28,376 | 24,560 | 20,857 |
| Impairment of goodwill and intangible assets | — | — | — | — | 0 | — | 5,000 | — |
| Total operating expenses | 140,159 | 127,591 | 157,135 | 153,622 | 117,950 | 68,795 | 79,693 | 60,696 |
| Operating loss | (139,159) | (123,991) | (157,135) | (146,122) | (117,950) | (68,545) | (78,081) | (58,847) |
| Other income, net | — | 5,748 | 2,673 | 582 | 1,557 | 4,059 | — | 2,700 |
| Other income, net | 8,232 | — | — | — | — | — | 4,204 | 2,700 |
| Net loss before income taxes | (130,927) | (118,243) | (154,462) | (145,540) | (116,393) | (64,486) | (73,877) | (56,147) |
| Income tax benefit | 0 | 1,078 | (74) | 0 | (1,114) | 0 | 1,250 | 0 |
| Net loss attributable to common stockholders | — | — | — | — | — | — | — | (56,147,000) |
| Net loss | (130,927) | (117,165) | (154,536) | (145,540) | (117,507) | (64,486) | (72,627) | — |
| Other comprehensive gain (loss): | ||||||||
| Net unrealized gain on marketable securities | 105 | 1,057 | (788) | (428) | 93 | 33 | 168 | (182) |
| Transfer of currency translation adjustments balance to other income related to the liquidation of foreign subsidiaries | — | — | — | 0 | 342 | — | — | — |
| Foreign currency translation adjustment | — | — | — | (25) | 29 | — | — | — |
| Foreign currency translation adjustment | (39) | 1 | (29) | — | — | 41 | (4) | (774) |
| Comprehensive loss | (130,861) | (116,107) | (155,353) | (145,993) | (117,043) | (64,412) | (72,463) | (57,103) |
| Net loss per share - basic and diluted (in dollars per share) | — | — | — | — | (1.38) | (1.01) | (1.18) | (1.29) |
| Weighted-average common shares outstanding-basic and diluted (in shares) | — | — | — | — | 85,146 | 64,102 | 61,375 | 43,661 |
| Net loss per share - basic (in USD per share) | (6.62) | (1.16) | (1.56) | (1.48) | — | — | — | — |
| Net loss per share - diluted (in USD per share) | (6.62) | (1.16) | (1.56) | (1.48) | — | — | — | — |
| Weighted-average common shares outstanding - basic (in shares) | 19,782 | 100,824 | 99,251 | 98,039 | — | — | — | — |
| Weighted-average common shares outstanding - diluted (in shares) | 19,782 | 100,824 | 99,251 | 98,039 | — | — | — | — |
| Collaboration and license revenue | — | — | — | — | — | — | — | 1,849,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.
Data on this page was fetched . The filing on SEC.gov is the record.